ZAP Surgical Announces Upcoming Installation of Next-Generation ZAP-X Gyroscopic Radiosurgery in Ankara, Turkey

ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, today announced that Hacettepe University Hospital in Ankara, Turkey is slated to install the novel ZAP-X® Gyroscopic Radiosurgery® platform before the end of the year. Patient treatments are expected to begin in early 2024.

Hacettepe University Hospital is among the highly esteemed Turkish institutions on the international platform and holds a leading position in medical education. Hacettepe has become the preeminent healthcare center of Turkey and proudly serves as a major training center for Hacettepe University Faculty of Medicine students and residents.

“When treating the brain with radiosurgery, every intricate detail matters to achieve the optimal outcome,” said Dr. Gokhan Ozyigit, Professor of Radiation Oncology at Hacettepe University. “Dedicated to treat only cranial indications without using Cobalt-60 radioactive sources, the ZAP-X will allow for world-class treatments that aren’t feasible with many multi-purpose radiotherapy systems designed to treat breast, lung, and prostate cancers. We have more than two decades of experience with stereotactic radiosurgery. Thus, we will not restrict ourselves only to treat brain lesions with ZAP-X, but also treat orbital and recurrent upper head and neck region tumors such as uveal melanomas and recurrent nasopharyngeal cancers. We are excited to further expand the world-class capabilities of our department with ZAP-X.”

Stereotactic radiosurgery (SRS) offers a non-invasive and painless procedure for many primary and metastatic brain tumors, as well as other cranial disorders such as trigeminal neuralgia and arteriovenous malformations (AVM). For select indications, radiosurgery has proven to provide equivalent to superior outcomes compared to costly and potentially debilitating surgeries. SRS is typically delivered in one to five brief outpatient visits and patients often return to normal activity the same day as the procedure.

With its ground-breaking design, the ZAP-X system uses unique gyroscopic mobility to direct radiosurgical beams from hundreds of unique angles to precisely concentrate radiation on the tumor target. This pioneering approach supports the clinical objective of protecting healthy brain tissue and preserving patient cognitive function. The vault-free, cobalt-free ZAP-X is also renowned for eliminating the expense of building costly shielded radiation treatment rooms, and removing the need to maintain, secure and regularly replace live radioactive isotopes for radiation beam production.

“Hacettepe University Hospital has always been at the forefront of the most advanced medical technology,” says Hakan Baraner, ZAP Surgical’s Senior Vice President for Europe, India, Middle East, and Africa (EIMEA). “With the addition of ZAP-X, they will further reinforce their reputation as global center of medical excellence.”

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”